Open AccessEvaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials
Author(s) -
M. Martín,
S. Loibl,
T. Hyslop,
Juan de la Haba-Rodríguez,
B. Aktas,
C.T. Cirrincione,
K. Mehta,
W.T. Barry,
S. Morales,
Lisa A. Carey,
J.A. Garcia-Saenz,
A. Partridge,
N. Martinez-Jañez,
O. Hahn,
E. Winer,
A. Guerrero-Zotano,
C. Hudis,
M. Casas,
C. Rodriguez-Martin,
J. Furlanetto,
E. Carrasco,
M.N. Dickler,
GEICAM Spanish Breast Cancer Group,
GBG,
Alliance for Clinical Trials in Oncology
Publication year - 2019
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/0xpa-s139
Subject(s) - bevacizumab , metastatic breast cancer , oncology , medicine , breast cancer , hormone receptor , endocrine system , first line treatment , cancer , hormone , chemotherapy